CRYSTALLINE RET INHIBITOR

VE6142021000071SUndetermined Publication Date: 2022-02-17LOXO ONCOLOGY INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
VE · VE
Patent Type
Designs
Current Assignee / Owner
LOXO ONCOLOGY INC
Filing Date
2021-04-07
Publication Date
2022-02-17
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art

Description

This document provides a crystalline form of selpercatinib useful in the treatment and prevention of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders, and methods for preparing this crystalline form.